RS66620B1 - Heterociklična jedinjenja za upotrebu u lečenju kancera - Google Patents

Heterociklična jedinjenja za upotrebu u lečenju kancera

Info

Publication number
RS66620B1
RS66620B1 RS20250272A RSP20250272A RS66620B1 RS 66620 B1 RS66620 B1 RS 66620B1 RS 20250272 A RS20250272 A RS 20250272A RS P20250272 A RSP20250272 A RS P20250272A RS 66620 B1 RS66620 B1 RS 66620B1
Authority
RS
Serbia
Prior art keywords
compound
compounds
formula
agents
inhibitors
Prior art date
Application number
RS20250272A
Other languages
English (en)
Serbian (sr)
Inventor
Owen Davis
Robert Heald
Martin Stockley
Harry Finch
Sam Mann
Original Assignee
Artios Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Artios Pharma Ltd filed Critical Artios Pharma Ltd
Publication of RS66620B1 publication Critical patent/RS66620B1/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RS20250272A 2021-10-21 2022-10-21 Heterociklična jedinjenja za upotrebu u lečenju kancera RS66620B1 (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB2115156.8A GB202115156D0 (en) 2021-10-21 2021-10-21 Novel compounds
EP22797829.3A EP4419526B1 (en) 2021-10-21 2022-10-21 Heterocyclic compounds for use in the treatment of cancer
PCT/GB2022/052690 WO2023067356A1 (en) 2021-10-21 2022-10-21 Heterocyclic compounds for use in the treatment of cancer

Publications (1)

Publication Number Publication Date
RS66620B1 true RS66620B1 (sr) 2025-04-30

Family

ID=78805918

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20250272A RS66620B1 (sr) 2021-10-21 2022-10-21 Heterociklična jedinjenja za upotrebu u lečenju kancera

Country Status (24)

Country Link
US (2) US20240425511A1 (cg-RX-API-DMAC7.html)
EP (2) EP4419527A1 (cg-RX-API-DMAC7.html)
JP (2) JP2024539132A (cg-RX-API-DMAC7.html)
KR (1) KR20240099274A (cg-RX-API-DMAC7.html)
CN (2) CN119053600A (cg-RX-API-DMAC7.html)
AR (1) AR127431A1 (cg-RX-API-DMAC7.html)
AU (1) AU2022374050A1 (cg-RX-API-DMAC7.html)
CA (1) CA3233255A1 (cg-RX-API-DMAC7.html)
DK (1) DK4419526T3 (cg-RX-API-DMAC7.html)
ES (1) ES3008687T3 (cg-RX-API-DMAC7.html)
FI (1) FI4419526T3 (cg-RX-API-DMAC7.html)
GB (1) GB202115156D0 (cg-RX-API-DMAC7.html)
HR (1) HRP20250334T1 (cg-RX-API-DMAC7.html)
HU (1) HUE070568T2 (cg-RX-API-DMAC7.html)
IL (1) IL311922A (cg-RX-API-DMAC7.html)
LT (1) LT4419526T (cg-RX-API-DMAC7.html)
MX (1) MX2024004874A (cg-RX-API-DMAC7.html)
PL (1) PL4419526T3 (cg-RX-API-DMAC7.html)
PT (1) PT4419526T (cg-RX-API-DMAC7.html)
RS (1) RS66620B1 (cg-RX-API-DMAC7.html)
SI (1) SI4419526T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202500123T1 (cg-RX-API-DMAC7.html)
TW (1) TW202334150A (cg-RX-API-DMAC7.html)
WO (2) WO2023067355A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202115156D0 (en) * 2021-10-21 2021-12-08 Artios Pharma Ltd Novel compounds
WO2025077896A1 (zh) * 2023-10-12 2025-04-17 上海湃隆生物科技有限公司 一种DNA聚合酶theta抑制剂及其应用
CN118084767B (zh) * 2024-04-02 2025-06-17 康龙化成手性医药技术(宁波)有限公司 一种外型-6-氟甲基-3-氮杂双环[3,1,0]己烷盐酸盐及其衍生物的合成方法
WO2025214463A1 (zh) * 2024-04-13 2025-10-16 正大天晴药业集团股份有限公司 含有三并环结构的化合物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10760081B2 (en) 2015-10-07 2020-09-01 New York University Compositions and methods for enhancing CRISPR activity by POLQ inhibition
EP4010080B1 (en) * 2019-08-09 2023-09-27 Artios Pharma Limited Heterocyclic compounds for use in the treatment of cancer
GB202115156D0 (en) * 2021-10-21 2021-12-08 Artios Pharma Ltd Novel compounds
GB202115158D0 (en) * 2021-10-21 2021-12-08 Artios Pharma Ltd Novel compounds
GB202115150D0 (en) * 2021-10-21 2021-12-08 Artios Pharma Ltd Novel compounds

Also Published As

Publication number Publication date
MX2024004874A (es) 2024-05-06
JP2024539132A (ja) 2024-10-28
CN118234728A (zh) 2024-06-21
SMT202500123T1 (it) 2025-05-12
EP4419526A1 (en) 2024-08-28
LT4419526T (lt) 2025-03-25
CN119053600A (zh) 2024-11-29
TW202334150A (zh) 2023-09-01
AU2022374050A1 (en) 2024-05-02
JP2024542949A (ja) 2024-11-19
WO2023067356A1 (en) 2023-04-27
PL4419526T3 (pl) 2025-04-22
US20240425511A1 (en) 2024-12-26
EP4419526B1 (en) 2024-12-25
EP4419527A1 (en) 2024-08-28
HUE070568T2 (hu) 2025-06-28
WO2023067355A1 (en) 2023-04-27
KR20240099274A (ko) 2024-06-28
ES3008687T3 (en) 2025-03-24
CA3233255A1 (en) 2023-04-27
SI4419526T1 (sl) 2025-05-30
DK4419526T3 (da) 2025-02-17
PT4419526T (pt) 2025-02-03
US20260124214A1 (en) 2026-05-07
FI4419526T3 (fi) 2025-02-13
AR127431A1 (es) 2024-01-24
HRP20250334T1 (hr) 2025-06-06
GB202115156D0 (en) 2021-12-08
IL311922A (en) 2024-06-01

Similar Documents

Publication Publication Date Title
ES2952281T3 (es) Compuestos deuterados para uso en el tratamiento del cáncer
US12358886B2 (en) Heterocyclic compounds for use in the treatment of cancer
US20240166623A1 (en) Novel process
US20250074900A1 (en) Isoindolinone inhibitors of the mdm2-p53 interaction and process for making them
EP4419526B1 (en) Heterocyclic compounds for use in the treatment of cancer
WO2021123785A1 (en) Dna polymerase theta inhibitors
EP4676602A1 (en) Compounds targeting mutations in p53 and uses thereof
WO2020030924A1 (en) Thiazoleureas as anticancer agents
HK40112378B (en) Heterocyclic compounds for use in the treatment of cancer
HK40112378A (en) Heterocyclic compounds for use in the treatment of cancer
WO2024218499A1 (en) Heterocyclic inhibitors of dna polymerase theta for the treatment of cancer
HK40076656A (en) Deuterated compounds for use in the treatment of cancer
HK40076656B (en) Deuterated compounds for use in the treatment of cancer
HK40078801A (en) Heterocyclic compounds for use in the treatment of cancer